
Opinion|Videos|July 29, 2024
Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do mutations associated like STK11, KEAP1, KRAS impact effectiveness of standard therapies and confer resistance?
- In real-world clinical practice, how frequently do patients with mNSCLC undergo comprehensive molecular and biomarker testing through techniques like NGS to evaluate for genetic alterations and potential targetable mutations?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Hereditary Ovarian Cancer Genes Found Beyond Traditionally High-Risk Groups
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
ACIP Delayed Hepatitis B Vaccine Schedule Vote Amid Safety Controversy
4
Medicaid Expansion Associated With Lower Mortality in NSCLC
5












































